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With the recent advances in the development of novel protein based therapeutics, controlled 
delivery of these biologics is an important area of research. Herein, we report the synthesis of 
microparticles from bovine serum albumin (BSA) as a model protein using Particle Replication in 
Non-wetting Templates (PRINT) with specific size and shape. These particles were functionalized 
at room temperature using multifunctional chlorosilane that cross-link the particles to render them 
to slowly-dissolving in aqueous media. Mass spectrometric study of the reaction products of 
diisopropyldichlorosilane with individual components of the particles revealed that they are 
capable of reacting and forming cross-links. Energy dispersive spectroscopy (EDS) and X-ray 
photoelectron spectroscopy (XPS) were also used to confirm the functionalization of the particles. 
Cross sectional analysis using focused ion beam (FIB) and EDS proved that the functionalization 
occurs throughout the bulk of the particles and is not just limited to the surface. Circular dichroism 
data confirmed that the fraction of BSA molecules released from the particles retains its secondary 
structure thereby indicating that the system can be used for delivering protein based formulations 
while controlling the dissolution kinetics.
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INTRODUCTION
Controlled delivery of protein based formulations to the site of interest is of high practical 
importance, due to the development of novel biomolecules with therapeutic potential.1 With 
the recent advances in biotechnology, monoclonal antibodies (mAb) are also being used as 
protein based therapeutic agents for treating different diseases.2 However, low 
bioavailability of these molecules makes their systemic delivery through the oral route quite 
challenging. This can be attributed to large molecular weight and hydrophilicity of these 
macromolecules that makes their absorption through biological membranes difficult.3,4 The 
ability to protect the active compound from the harsh conditions of the gastrointestinal tract 
and enzymatic barrier are other challenges in oral delivery of proteins, since the delicate 
structure of these molecules is prone to different modes of instabilities.4,5 Due to less than 
1% oral bioavailability of the initial dose, proteins are normally administered by either 
injection or infusion in aqueous solutions.4,6–8 Local delivery to a specific site using 
intratumoral,9,10 intravitreal,11 epidural,12 and intra-articular13 routes is desirable as it 
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significantly reduces the therapeutic drug dose and adverse side effects associated with the 
undesirable distribution in various tissues and organs.14 Other noninvasive alternative routes 
suffer from the fact that, in the absence of a membrane permeation enhancer, the absorption 
is much less than that of parenteral administration while toxicity is a major drawback of 
using these enhancers in the formulation.14,15
According to Almeida and Souto,1 the established method of protein delivery consists of 
attaching the drugs to a proper particulate carrier, where the fate of the drug molecule is 
determined by the properties of the carrier rather than those of the protein. Therefore, use of 
an appropriate delivery vehicle that can protect proteins from enzymatic degradation and 
control the release rate is a promising approach for prolonged retention while saving the 
biological activity of the drug.16
There are several studies that address different systems for protein/antibody delivery. Lee 
and Yuk16 review both polymeric hydrogel carriers and liposomal systems for delivery of 
proteins. One of the obstacles in the development of a suitable polymeric carrier for protein 
drugs is low drug loading.10 A possible solution to this problem is preparation of particles 
that are made from a protein based carrier instead of a polymer. Several researchers have 
tried to prepare particulate systems that do not rely on a carrier polymer for delivering the 
protein. Yang et al.17 have developed methods to produce crystalline suspensions of 
approved therapeutic mAbs. Miller et al.18 studied highly concentrated suspensions of 
lysozyme powder in a nonaqueous mixture of safflower oil and benzyl benzoate. α-Amylase 
crystals have been suspended in sucrose acetate isobutyrate plasticized with ethanol as a 
potential in situ formable protein depot.6
Preparation of cross-linked albumin nano/microparticles has been reported in the literature 
using suspension technology,19,20 layer-by-layer assembly,21,22 spray-drying,23 and 
desolvation/coacervation.24,25 These methods rely on heat treatment for self-cross-linking 
through formation of interchain amide links or chemical treatment with a stabilizer such as 
glutaraldehyde (GA) and butanedione to confer dimensional stability. GA reacts with amino 
groups of the protein while butanedione reacts with the guanidinyl moiety of arginine 
residue to form uncleavable chemical cross-links. In addition to the irreversible cross-
linking reaction of these stabilizers, the shapes of the fabricated particles are limited to 
spheres, capsules, and rods. Bogdansky26 gives a detailed insight into the use of albumin 
based particles for therapeutic applications. The advantage of the albumin based particulate 
system is the lack of toxicity and degradation into natural products. Albumin based particles 
containing proteins have been examined as potential drug delivery systems by other 
researchers. Urokinase has been immobilized in GA cross-linked bovine serum albumin 
(BSA) particles by Bhargava and Ando,27 and GA cross-linked insulin-BSA microbeads 
were prepared by Goosen et al.28 Human serum albumin (HSA) nanocapsules were prepared 
by Rollett et al.29 for targeted drug delivery to activated macrophages. Application of 
albumin microspheres (3–4 μm) to pro-inflammatory cytokine inhibition was reviewed by 
Oettinger and D’Souza,30 and versatility of albumin as a drug carrier was evaluated by 
Kratz.31 Doshi and Mitragotri32 demonstrated that both size and shape of polymeric 
particles critically control their elimination by macrophages. Therefore, precise control over 
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size and shape is desirable for controlling the clearance time of the particles upon local 
delivery.
According to Lee et al.,33 injectable beads prepared by cross-linking BSA under mild 
conditions using GA should yield a nonimmunogenic and biodegradable device for drug 
delivery and have been used for sustained release of progesterone. Furthermore, Ratcliffe et 
al.34 tested the in vivo biocompatibility of poly(lactic acid), poly(butyl cyanoacrylate), 
gelatin, and GA cross-linked homologous albumin microspheres (1.9 ± 1.5 μm) with rabbit’s 
synovial tissues upon intra-articular injection. They concluded that albumin microspheres 
are the most acceptable polymer among the ones studied. The slight hyperplasia observed by 
the authors in the synovial membrane was attributed to denaturation of albumin with GA.
Numerous pH cleavable linkers such as acetals, ketals, ortho esters,35,36 bis-pyridoxal 
polyphosphates,37 and the derivative of 2-methylmaleic anhydride38 have been developed 
for cross-linking proteins. Silyl ethers have also been successfully used for reversibly cross-
linking precision particles made from hydroxyethyl acrylate and controlling the release 
kinetics based on the pH of the environment and size of the substituents on the silicon 
atom.39
The objective of this work was to fabricate suspensions of protein particles with controlled 
size and shape capable of slowly releasing the protein based therapeutic in aqueous media 
exploiting the pH cleavability of the silyl ether bond in cross-linked particles. This carrier 
system can be used for local delivery of the biomolecules to the site of interest while 
maintaining protein concentration within the therapeutic window. The outcome of this work 
demonstrates the ability to effectively increase the retention time of the protein based 
therapeutics deliverable through the parenteral route by fine-tuning the silylation reaction 
and can potentially maximize the efficacy of the drug.
EXPERIMENTAL SECTION
Materials
BSA, diisopropyldichlorosilane (DIDCS), and formic acid (FA) were obtained from Sigma-
Aldrich. Extra-dry acetonitrile (ACN), trifluoroacetic acid (TFA), α-D-lactose monohydrate 
(lactose), glycerol, and extra-dry isopropanol (IPA) were all ACROS products obtained 
through Fisher Scientific. Standard buffers of pH 7.4 and 10.0, as well as HPLC grade water 
and acetonitrile, were all obtained through Fisher Scientific. The Alexa Fluor 555 
conjugated BSA was purchased from Life Technologies.
Particle Fabrication
Particle Replication in Non-wetting Templates (PRINT) platform has been previously used 
to fabricate monodisperse, shape-specific albumin particles.40 In this work, PRINT was used 
to make particles from a mixture of BSA, lactose, and glycerol (40/40/20 wt %) in deionized 
water (18.2 MΩ·cm). The mixture was rolled and dried into the form of a solid flat sheet on 
the surface of a poly(ethylene terephthalate) film using Mayer rod on EZ Coater EC-200 
(ChemInstruments) which is then used to fill the donut-shaped micron-sized molds. The 
filling process was carried out using a commercially available hot roll laminator 
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(ChemInstruments) at 414 kPa and 138 °C as measured by Thermax Range C (TMC 
Hallcrest) temperature indicator films. Lactose was added to the formulation to lower the 
softening temperature of BSA and to make it moldable in the PRINT process. Glycerol 
merely serves as a processing aid during the filling stage. The particles were then transferred 
to a harvesting film made from Luvitec VA 64 (BASF) in a heated laminator (total 
lamination time of less than 30 s). Particles were freed from the harvesting film by 
dissolving the adhesive in extra-dry ACN. Due to the fact that the solubility of BSA in ACN 
is minimal (0.02 mg/mL),41 it was possible to separate these particles from the Luvitec layer 
through consecutive washing without any recognizable changes to the structural integrity of 
the particles. Furthermore, the secondary structure of the protein was expected to remain 
intact in the absence of water when using extra-dry ACN.42
Particle Composition
The composition of particles was determined using a high-performance liquid 
chromatography (HPLC) instrument (1260 Infinity by Agilent) equipped with an 
evaporative light scattering detector. The HPLC method used was based on separating BSA 
from lactose and glycerol using an Ultracel-30K Amicon Ultra centrifugal filter (Millipore) 
and then running them on two different columns based on reversed phase chromatography 
using a Poroshell 300SB-C8 column (Agilent) for the BSA in the mixture and ion exchange 
chromatography using a Hi-Plex Ca column (Agilent) for lactose and glycerol (Table S1, 
Supporting Information).
Functionalization (Silylation)
In this work, silylation based on chlorosilanes was carried out on particles after harvesting 
them in ACN. The mass of the harvested particles was determined using thermogravimetric 
analysis (TGA Q5000-TA Instruments). Particles (5 mg) were dispersed in ACN (4.7 mL), 
and then DIDCS (1.27 mL) was added while allowing the reaction (rx) to proceed for 6, 12, 
and 24 hour (hr) in separate vials. At the end of the treatment with the chlorosilane, the 
particles were washed with IPA which quenched the reaction at the desired time point and 
enabled the removal of unreacted DIDCS. The silylation process on the particles and 
introduction of a silyl group in place of the labile hydrogen atoms upon exposure to DIDCS 
result in the formation of cross-links (Figure S1, Supporting Information). The amino acid 
composition of BSA43,44 contains multiple residues with labile hydrogen atoms (e.g., Tyr, 
Ser) that can serve as an anchor point for attachment of diisopropyl groups. Therefore, it is 
expected that multiple residues participate in the reaction. The byproduct of the reaction is 
hydrochloric acid which is expected to behave as a weak acid in pure ACN (acid 
dissociation constant (pKHA) of 8.9).45
Chemical Characterization
Mass Spectrometry (MS)—To understand the interaction of chlorosilane with the 
components of the particles, mass spectrometric analysis using electrospray ionization (ESI) 
was performed on the individual ingredients of the particles. BSA powder was pulverized in 
an agate pestle and mortar combination and passed through a 400 mesh sieve (38 μm 
nominal opening) to get a fine dry powder. This powder (20 mg) was then dispersed in 
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extra-dry ACN (12 mL), and DIDCS (5 mL) was later added to the mixture. The silylation 
reaction was allowed to proceed for 12–24 hr and then neutralized with IPA at the end of the 
experiment. BSA crystals were then spun down and washed with extra IPA to remove 
unreacted and physisorbed DIDCS. Intact and silylated samples were all purified and 
isolated by centrifugal filtration of the aqueous solution through Amicon Ultracel-30K 
filters. Silylated samples were dialyzed (Slide-A-Lyzer dialysis cassette, Pierce, 20 000 
MWCO) overnight in HPLC grade water. Samples (5 mg/mL) were then directly injected 
into the LTQ-FT mass spectrometer (Thermo Fisher Scientific) and analyzed in positive ion 
trap mode (600–2000 m/z). Typically, the sample (0.5 mL) was mixed with HPLC grade 
ACN (1 mL) and FA in HPLC grade water (3 v/v%, 0.5 mL). The instrument was externally 
calibrated with a resolution setting of 100 000. ProMass (Novatia) software was used for 
deconvolution of the intact and modified protein spectra to obtain the molecular weights. 
High baseline removal (1.2) was used in the deconvolution algorithm, and the output range 
was set to 40 000–100 000 Daltons (Da).
Reaction products of glycerol with DIDCS were analyzed using the same mass spectrometer 
in Fourier transform (FT) mode. Glycerol (1 mL) was mixed with DIDCS (1 mL), and the 
reaction was allowed to proceed for 3 days when it was finally neutralized with IPA (3 mL). 
The reaction mixture was then directly injected to the mass spectrometer without addition of 
water to prevent desilylation of the reaction products.
EDS/FIB/XPS—The nature of functionalization at the individual particle level was 
analyzed by energy dispersive spectroscopy (EDS) using INCA (Oxford Instruments) on the 
FEI Helios 600 Nanolab Dual Beam System which was also used for cross sectional study. 
Individual particle analysis was done by drying the particles over the surface of copper tape 
and then coating them with 3 nm gold (Au)/ palladium (Pd) (Cressington sputter coater 108 
auto). Three different random particles per each sample were analyzed to quantify the 
amount of silicon. For cross sectional analysis using focused ion beam (FIB), particles were 
dried over the surface of a carbon planchet (Electron Microscopy Services) and coated with 
carbon [10.5 nm] in a high resolution ion beam coater (Gatan 681) to prevent 
redepositioning of Au/Pd upon cutting the particle at 30.0 kV with 9.7 pA Gallium ion (Ga+) 
current. Linescans at 5.0 kV were then performed on the particle to measure the variation of 
elements across the particle cross section.
X-ray photoelectron spectroscopy (XPS) using the monochromatic Al Kα source (1486.6 
eV) of Kratos Axis Ultra (150 W) was used to investigate the structural changes and to 
follow the cross-linking chemistry. Particles were deposited on Au [65 nm]/titanium (Ti) [15 
nm] covered silicon wafers, and two different points on each sample were analyzed; then, 
the measured values were averaged. During these experiments, the charge neutralizer was 
on. Four sweeps of 800 ms dwelling time were used for sulfur (S 2p), silicon (Si 2p, Si 2s), 
and chlorine (Cl 2p), while for carbon (C 1s), oxygen (O 1s), and nitrogen (N 1s) only one 
sweep of 800 ms was performed for each peak. Individual peaks were fitted with Gaussian–
Lorentzian shape (GL[30]) curves, and locations of the components were compared against 
the values reported in the literature after shifting the peaks for +0.24 eV to fix the aliphatic 
carbon peak at 285.0 eV.
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SEM/TEM/Optical Microscopy—Scanning electron microscopy (SEM) images were 
obtained on a Hitachi S-4700 Cold Cathode Field Emission Scanning Electron Microscope 
by coating the samples with 3 nm of Au/Pd alloy. Transmission electron microscopy (TEM) 
was carried by first staining the particles with osmium tetroxide through vapor deposition, 
and then, an image was obtained using JEOL 2010F-FasTEM on a copper grid. 
Postfabrication particle size measurements were carried on a dry sample by performing 28 
different measurements on SEM images using ImageJ.46 Optical images of the particles 
were obtained with a LSM 700 (Zeiss) microscope in fluorescent channel.
Circular Dichroism
Circular dichroism (CD) spectra were obtained with Chirascan Plus spectrometer (Applied 
Photophysics) in a cell with a path length (d) of 0.1 cm at room temperature from 190 to 240 
nm. Coomassie plus colorimetric assay (Thermo Scientific) was used to determine the 
protein concentration (c g/L). Solutions (15 μL) were mixed with assay reagent (300 μL), 
and the absorbance was measured at 595 nm (25–500 μg/mL). Concentrations obtained from 
the protein assay were then used to convert the CD data (θλ millidegrees at specific 
wavelength λ) to Δε molar differential extinction coefficient per residue (M−1cm−1) 
assuming a mean residue weight (MRW) of 114.15 Da for BSA prior to and 
postmodification (Δε = ((MRW × θλ)/(c × 10 × 3298 × d))). CDPro software (Colorado State 
University) was used to analyze the CD spectra and quantify the structure. The spectra were 
fitted with CONTINLL subroutine using 7 bases, and the secondary structure of the protein 
was estimated by deconvoluting the peaks and calculating the percentage of helical, beta, 
turn, and random components of the molecule.47
Modified particles reacted for 24 h, and unmodified control particles were dissolved in pH 
7.4 buffer for a period of 18 h at 4 °C and then diluted in 10 mM K2HPO4. For control 
particles (202 μg/mL) and those reacted for 24 h (82.5 μg/mL), concentrations were 
determined with coomassie plus assay. Melting experiment of BSA was done by heating a 
solution (350 μg/mL) using QNW temperature control from 25 to 95 °C to determine the 
structure of the heat denatured molecule.
Alexa Fluor 555 BSA Conjugate Loading
Alexa Fluor 555 conjugated BSA (5 mg) was loaded into the preparticle solution (per 250 
mg of BSA) to fabricate fluorescent particles for studying the dissolution mechanism and 
kinetics. To understand the dissolution/ desilylation process, particles were reacted with 
DIDCS for 6, 12, and 24 h, and then, the resulting material was exposed to pH 7.4 buffer to 
measure the fractional release of Alexa Fluor 555 conjugated BSA. Several different 
aliquots containing particles (3.13 mg) were prepared for each specific time point (15, 60, 
150, 300, and 600 min). Each aliquot was then reconstituted in pH 7.4 buffer (600 μL), and 
at each time point, the particles were spun down and the supernatant (100 μL) was analyzed 
in triplicate by measuring the fluorescence intensity (Excitation: 545 nm; Emission: 575 nm) 
using SpectraMax M5 (Molecular Devices) in Nunc 96 microwell plates (Thermo 
Scientific). The intensity of soluble unfunctionalized particles at 600 min served as the 
control reference in calculation of the fractional dye release from the particles.
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Fitting and Statistical Analysis
All the model fittings were done by JMP software (SAS Institute), and p values for 
statistical significances were calculated by QuickCalcs (GraphPad) online statistical 
calculator.
RESULTS AND DISCUSSION
Particle Fabrication and Composition
A SEM image of sieved BSA powder is shown in Figure 1A while that of the particles as 
fabricated with PRINT on the surface of the harvesting layer is displayed in Figure 1B. 
Harvested free particles of Figure 1C are obtained by washing them with ACN. A TEM 
image of the free particles is presented in Figure 1E. The composition of the particles 
postfabrication was determined to be 55.7 wt % BSA, 43.1 wt % lactose, and 1.2 wt % 
glycerol as schematically shown in Figure 1D. These particles were further loaded with 
Alexa Fluor 555 conjugated BSA as seen in Figure 1G. The mean external and internal 
diameters plus the thickness of the particles were measured as 2.88 ± 0.21, 0.7 ± 0.06, 0.56 
± 0.17 μm, respectively (Figure 1F).
Component Reactivity
Silylation is extensively used in organic chemistry to block certain reaction centers by 
introducing a silyl group in place of a labile hydrogen atom. Silylation reactions are 
reversible and proceed via a mechanism involving bimolecular nucleophilic substitution at 
the silicon atom. In many cases, the mechanism and rate of silylation are determined by the 
steric factors associated with the silylating agent or the compound being silylated.48 
Rogozhin et al.49 have derivatized amino acids (Pro, Tyr, Trp, Val, Asp, Lys) and dipeptides 
(Gly-Ala, Val-Val, Gly-Tyr, Gly-Trp) with different silylating agents 
(trimethylsilyldiethylamine, bis(trimethylsilyl) acetamide, N-trimethylsilyl-N-
methylacetamide, and hexamethyldisilazane) in organic solvents at 20 °C.
Silylation with chlorosilanes has been previously used by several authors on nonprotein/
peptide based materials to alter the surface properties or incorporate drugs into polymeric 
matrices. Chlorosilanes have been used on multiwall carbon nanotubes to functionalize their 
surface.50 Gousse et al.51 modified cellulose whisker dispersed in organic solvents and 
concluded that it is possible to partially silylate the whiskers where the surface of the 
whiskers is silylated but the core is kept almost intact. Silylether chemistry has also been 
used for incorporating drugs into the matrix of particles as a pro-drug strategy with hydroxyl 
ethyl acrylate.52
Figure 2A compares the spectra of dialyzed BSA post-functionalization (12–24 h) with 
intact material. After 12 hr of functionalization, mass over charge (m/z) peaks for BSA are 
shifted toward higher values, which serves as the evidence of functionalization with DIDCS 
(Figure 2B). Exposure of BSA to DIDCS for 24 h causes formation of visible precipitates. 
However, due to low signal intensity after 24 h of silylation, no conclusions could be drawn 
regarding this sample. Once the spectra for intact and 12 hr modified samples are 
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deconvoluted, an increase in the molecular weight of the BSA due to silylation is observed 
as illustrated in Figure 2C.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) evaluation of the structure 
of trypsin digested 12 hr functionalized BSA molecules did not reveal any detectable 
modification of the recovered peptidic sequence. This can be attributed to the susceptibility 
of the bonds formed to hydrolysis during the digestion period.
Glycerol is capable of forming a variety of combinations with DIDCS under the reaction 
conditions (Figure S2, Supporting Information). The proposed structures are shown in 
Figure 3 for compounds A through H. The most abundant component is compound E formed 
from the reaction of two equivalents of DIDCS with one equivalent of glycerol. Although 
less abundant compared to compound E, multiple glycerol molecules can also be linked 
together due to the multifunctionality of both DIDCS (2 × chlorine [Cl]) and glycerol (3 × 
hydroxyl [OH]) as confirmed by the presence of compounds D, G, and H. Furthermore, the 
reaction conditions are conducive to the formation of larger fragments. Nevertheless, 
assigning structures to these peaks is not straightforward due to a multitude of combinations. 
Errors involved between the observed and theoretical masses of the identified peaks are 
presented in Table S2, Supporting Information.
No evidence of reactivity of lactose with DIDCS could be detected under the reaction 
conditions. Although lactose bears multiple hydroxyl groups, we believe that insolubility of 
the material makes it immune to solid state functionalization carried in extra-dry ACN. 
Lactose is not soluble in acetonitrile–water mixtures containing less than 15% water.53
Particle Ensemble Analysis
XPS is a powerful technique for detecting compositional variations on the surface that are 
induced by silanization.54 The amount of silicon on the surface of the particles was 
measured with XPS, and relative intensities of the peaks are plotted in Figure 4A. The sulfur 
(S 2p) peak serves as a protein marker (disulfide bond-cysteine) and therefore was used as 
the appropriate reference element for comparing and quantifying the relative intensities of 
each peak. Both silicon (Si 2s) and (Si 2p) peaks increase with respect to sulfur (S 2p) as a 
function of reaction time. However, the data for Si 2s is not shown for brevity. High 
resolution peaks of silicon (Si 2s, Si 2p) and sulfur (S 2p) for unmodified and reacted 
samples along with the survey scans are compared in Figure S3, Supporting Information. 
High resolution scans of oxygen (O 1s), carbon (C 1s), and nitrogen (N 1s) peaks were 
performed to detect any chemical changes associated with functionalization. Figure 4B,C 
compares oxygen (O 1s) scans for unmodified particles and the sample silylated for 24 hr. 
The shifted values of the binding energies for the deconvoluted components are listed in 
Table S3, Supporting Information.
Lopez and co-workers55 reported the value of 532.8 eV for the oxygen (O 1s) peak of 1,10-
decanediol and 532.7 eV for poly(vinyl alcohol) and poly(propylene glycol) with reference 
to an aliphatic carbon peak at 285.0 eV. Therefore, it can be concluded that the reduction in 
the intensity of the oxygen (O 1s) peak (labeled B) is consistent with consumption of 
hydroxyl groups on the surface due to the functionalization after 24 hr. The oxygen (O 1s) 
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peak (labeled A) of 531.4 eV is very close to peptidic oxygen of BSA as reported by Iucci et 
al.56 at 531.6 eV. Carbon (C 1s) and nitrogen (N 1s) scans for the same samples are also 
presented in Figure S4, Supporting Information.
Individual Particle Analysis
A representative particle prior to exposure to the electron beam of EDS is shown in Figure 
5A. Post-EDS analysis, the particle retains its shape, although there is minor structural 
damage due to the electron beam (Figure 5B). Elemental mapping at 20.0 kV over the top 
surface of the particle qualitatively confirmed the presence of silicon (Si) in the particle as 
illustrated in Figure 5C. Elemental maps of oxygen (O), sulfur (S), chlorine (Cl), nitrogen 
(N), and carbon (C) are also shown in Figure 5D–H for comparison. The corresponding 
spectrum obtained from elemental mapping of the particle in Figure 5 is shown in Figure S5, 
Supporting Information.
Quantification of the degree of silylation on the particles is done by analyzing an area on the 
top surface of the particles (pink rectangle in Figure 5J). Three different particles of silylated 
samples are analyzed, and the result is averaged and presented in Figure 5I. The statistical 
significances and silicon content variation among these distinct sets of samples/particles are 
also shown in this figure for comparison. It can be concluded that longer exposure to DIDCS 
results in a higher ratio of Si/S, Si/O, and Si/C in the particles.
Cross Sectional Analysis
Figure 6C,D shows the top and side views of a particle after being cross sectioned with the 
FIB, respectively. The distribution of the elements along the yellow line depicted in Figure 
6D is plotted in Figure 6B as a function of transverse distance. The sum spectrum of the 
linescan is also compared with the spectrum of the background to confirm that no silicon 
signal is detected on the carbon background (Figure 6A). No variation could be observed in 
the silicon content along the scanned line of Figure 6D, which suggests that DIDCS 
penetrates all the way through the particle and the reaction is not limited only to the surface 
of the particle.
Mechanism and Dissolution Profile
To study the dissolution of particles, silylated particles were exposed to pH 7.4 buffer and 
the fractional release of Alexa Fluor 555 conjugated BSA was measured (Figure 7A, 
symbols). The data demonstrates that the longer the treatment of particles with DIDCS, the 
slower is the dissolution rate of the particles. This is consistent with the higher silicon 
content of the particles as a function of reaction time, obtained from EDS and XPS 
experiments.
Numerous mathematical models exist in the literature for describing the dissolution 
behavior.57,58 Weibull59 and Korsmeyer-Peppas60 models are fitted to the experimental data 
(Figure 7A, lines), and corresponding model parameters are listed in Table S4, Supporting 
Information. The diffusional exponent in the Korsmeyer-Peppas model is indicative of a 
release mechanism (mode of transport of solute) and is shape dependent.61
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To visualize the dissolution process for particles post-functionalization, the behavior of a 
single 12 hr silylated particle is tracked in pH 7.4 buffer as a function of time. As observed 
in Figure 7B, the intensity of Alexa Fluor 555 conjugated BSA in the particle gradually 
diminishes due to dissolution of the fluorophore from the particle into the surrounding 
environment. Effects of both acidic (0.1 v/v% TFA, approximate pH = 2.0) and basic (pH 
10.0 buffer) conditions on the size of particles are illustrated in Figure 7C,E for particles 
functionalized for 24 hr, respectively. At these pH extremes, particles significantly swell to 
4–5 times their original size of Figure 7D. Shirai et al.62 have studied the effect of different 
pHs on the hydrolytic removal of silyl groups from trialkyl silyl ethers. Their results indicate 
that there exists a pH where the observed hydrolysis rate constants are minimized. They 
demonstrated that this rate of hydrolysis is also affected by the electronegativity and steric 
size of the substituents on both silicon and oxygen atoms. The extreme swelling of these 
particles in both acidic and basic conditions suggests that the prevailing mechanism of 
dissolution is desilylation (removal of silyl groups).
The extreme swelling of the particles in acidic pH as observed in Figure 7C leaves the 
protein content of the particles prone to degradation in the harsh acidic environment of the 
gastrointestinal tract, and therefore, an oral delivery route for these suspensions is not 
envisioned. A measure for the stability of the suspension of 24 hr functionalized particles in 
pH 7.4 buffer is presented in Figure S6, Supporting Information.
Structural Evaluation
CD signal can determine structural changes associated with processing or functionalization 
of the protein in the particles. An examination of the melting behavior of intact BSA was 
done to evaluate the structural changes associated with heat denaturation of the molecule, 
which will enable us to compare the structures of processed BSA to that of the intact or 
denatured molecule (Figure 8C). It can be seen that the intensity of the peaks at 209 and 222 
nm is greatly reduced upon heating the sample. Figure 8C merely serves as a reference on 
how the structure of thermally denatured BSA evolves and illustrates the significant 
reduction in the helical structure upon thermal denaturation.
CD data for unmodified and modified particles are presented in Figure 8A and compared to 
intact and heat denatured BSA. Houen et al.63 showed that denatured BSA has limited 
solubility in water, and thus, structural changes postdenaturation are expected to be 
detectable with CD. Figure 8B shows the corresponding structural components obtained 
from deconvoluting/fitting the CD spectra while accuracy of the fits to the experimental data 
is examined in Figure 8A. The data in Figure 8B suggests that the silylation process used 
herein did not perturb the secondary structure of the fraction of BSA molecules that were 
dissolved in the buffer through the course of the dissolution experiment. Moreover, no 
evidence of thermal denaturation post particle fabrication could be obtained, primarily due 
to the fact that the denaturation mechanism is a time dependent process.64 This method of 
analysis had been used by Harn et al.2 to analyze the structure of recombinant humanized 
IgG1κ and also by Estey et al.65 to study the degradation of BSA under acidic conditions.
Aggregates of denatured protein can induce antibody, but they are not expected to induce 
neutralizing antibody due to lost protein conformation on denaturation. Formation of 
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natively conformed aggregates on the other hand can be detrimental for therapeutic proteins 
due to the generation of neutralizing antibody response.66 Although subvisible particles less 
than 10 μm are not being evaluated in the USP 〈788〉 test, they can potentially impact 
clinical performance.67 Nevertheless, Singh et al.68 emphasize the uncertainty around the 
potential immunogenicity risk of subvisible particles in pharmaceutical formulations and 
conclude that the direct link between aggregation and clinical immunogenicity is not well 
established. They also assert that preclinical studies are not yet capable of evaluating the 
immunogenicity potential of product attributes such as aggregates and particles smaller than 
10 μm. Experiments of van Beers et al.69 with different structures of recombinant human 
interferon Beta-1a proved that large unreacted aggregates (3.2 μm) and guanidine treated 
aggregated molecules (0.35 μm) are not necessarily immunogenic in transgenic immune-
tolerant mice. The relation between structure and immunogenicity of recombinant human 
interferon Alpha-2b was investigated in wild-type and transgenic mice by Hermeling et 
al.,70 and no antibody responses for GA cross-linked molecule were detected. Moreover, 
boiled/denatured molecules (1–3 μm) proved to be poor immunogens in transgenic mice.
CONCLUSIONS
We have demonstrated that the combination of PRINT technology and silylation provides a 
valuable tool for tuning the solubility of the protein particles while controlling their size and 
shape. EDS and XPS confirm the modification at the particle and ensemble levels, 
respectively. The silylation process renders the solubility of the particles to be tunable, 
eventually dissolving in aqueous media while not perturbing the secondary structure of the 
fraction of BSA released from the particles. The rate of dissolution can be controlled by the 
time particles spend in the functionalization media consisting of extra-dry acetonitrile and 
diisopropyldichlorosilane. Extreme swelling of the particles in low and high pH confirms 
that desilylation is the mechanism of particle dissolution. To further understand the nature of 
functionalization, EDS cross sectional analysis confirmed that the chlorosilane diffuses all 
the way through the particles and is not just limited to the surface.
Lowering the temperature used in the filling/harvesting stages of the particle fabrication 
enables us to better protect the sensitive contents of the particles against various modes of 
instabilities. Fabricating particles from homologous albumin instead of a heterologous one is 
recommended as it allows us to prepare particles that are made from nonimmunogenic 
ingredients. Immunogenicity of our subvisible functionalized particles loaded with a 
therapeutic protein will be thoroughly investigated in future, to elucidate the role of 
functionalization and fabrication parameters. In vivo behavior of these functionalized 
particles and their potential in extending protein retention is a subject of a separate study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) BSA powder ground and sieved through a 400 mesh screen. (B) SEM of the particles 
obtained on the harvesting layer. (C) SEM of free particles after washing with ACN. (D) 
Particle composition postfabrication (blue: lactose; red: glycerol; green: BSA). (E) TEM of 
the particles. (F) Particle size as measured by image analysis using ImageJ (n = 28). (G) 
Particles loaded with Alexa Fluor 555 conjugated BSA on the surface of the harvesting layer 
(Excitation: 555 nm; Long pass filter: 560 nm).
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Mass spectra of BSA prior to (black) and after functionalization (red: 12 hr; green: 24 hr of 
silylation): (A) m/z range 1000–1600 and (B) m/z range 1400–1500. (C) Deconvoluted 
spectra of intact and modified BSA samples using ProMass software.
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Identified reaction compounds of glycerol with DIDCS. (A) C9H20O3Si, (B) C12H28O4Si, 
(C) C12H30O3Si2, (D) C12H28O6Si, (E) C15H34O4Si2, (F) C18H42O5Si2, (G) C18H40O6Si2, 
and (H) C18H42O7Si2.
Khodabandehlou et al. Page 19














(A) Average ratio of silicon to sulfur (Si 2p/S 2p) for particle ensemble as a function of 
reaction time (n = 2). High resolution XPS peaks (experimental: square, predicted/fitted: 
black line) and corresponding components (O 1sA: red line; O 1sB: green line; O 1sC: blue 
line) of (B) O 1s unmodified and (C) O 1s 24 hr silylated samples (cps: counts per second).
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Elemental mapping (20.0 kV) of the particle silylated for 24 hr. (A) Particle prior to EDS 
beam exposure. (B) Particle after exposure to EDS beam. (C) Si Kα, (D) O Kα, (E) S Kα, 
(F) Cl Kα, (G) N Kα, and (H) C Kα. (I) EDS analysis of individual particles and calculation 
of Si/O (red), Si/C (blue), and Si/S (green) ratios as a function of reaction time. (J) The 
scanned area on top of an individual particle is shown with a pink rectangle (n = 3).
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(A) Sum of the elemental spectrum along the EDS linescan on the particle sectioned using 
FIB compared to the spectrum of the carbon background (5.0 kV). (B) Distribution of the 
elements along the linescan (red: silicon; blue: sulfur; green: chlorine; black: oxygen; 
burgundy: gallium). (C) Top view of the FIB sectioned particle. (D) Side view of the same 
particle (yellow line indicates the position of the line used to perform the EDS analysis).
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(A) Fractional dye release (n = 3, 0–600 min) from the particles at pH 7.4 as a function of 
reaction time (6 h: diamond; 12 hr: rectangle; 24 hr: triangle) and corresponding fits to 
Korsmeyer-Peppas (continuous line) and Weibull models (dashed line). (B) Time lapse 
images (every 30 min) of a 12 hr silylated particle containing Alexa Fluor 555 conjugated 
BSA placed in a vat of pH 7.4 buffer showing the gradual migration of the dye from the 
particle (Sequence starts at image 1 and ends at image 10; Excitation: 555 nm; Long pass 
filter: 560 nm). Particles silylated for 24 hr. (C) 0.1 v/v% TFA in water, approximate pH = 
2.0, (D) dry, and (E) pH 10.0 buffer (Excitation: 555 nm; Long pass filter: 560 nm).
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(A) CD spectra for heat denatured BSA (circle), intact BSA (diamond), unfunctionalized 
control particles (square), and functionalized particles for 24 hr (triangle). Corresponding 
fits using CDPro software are also shown (lines). (B) Contribution of each structure after 
deconvolution (green: helical; yellow: beta; blue: turn; red: random). (C) CD signal at 222 
nm (triangle) and 209 nm (circle) as a function of temperature (°C) for BSA solution and the 
associated heat denaturation of the molecule.
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